Vanessa Yen was quoted by Law360 in an article about how biotech companies engage in exchanging patent information with each other. 

Vanessa comments on Purple Book listings saying, "The Purple Book is not telling you which biosimilar the patent dance exchange was with, when the exchanges were done, whether there are multiple exchanges with multiple similars. It's really just a list of integrated products and patent numbers."

Source

Law360